Hospital
Buchanan General Hospital, INC
Buchanan General Hospital, INC was paid $11.20M by Medicaid between Jan 2018 and Dec 2024, across 178 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoBUCHANAN GENERAL HOSPITAL, INC
GRUNDY, VA 24614
GRUNDY, VA 24614
33aNPI1225036346assigned 07/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.20M
24GClaims485,735
24DCodes billed178
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#49 of 80
Median peer was paid$14.69M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,732 | $1.24M | |
| 2019 | 72,124 | $1.41M | |
| 2020 | 60,085 | $1.49M | |
| 2021 | 68,208 | $1.62M | |
| 2022 | 71,823 | $1.87M | |
| 2023 | 80,251 | $1.98M | |
| 2024incomplete | 65,512 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 11,939 | 9,832 | $1.65M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 10,880 | 9,475 | $1.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 10,799 | 9,050 | $1.39M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.0% | 3,535 | 2,693 | $782K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.3% | 3,672 | 3,143 | $599K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.9% | 3,110 | 2,747 | $547K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 2,458 | 2,117 | $517K |
| G0378 | Hospital observation service, per hour | 3.5% | 2,036 | 1,640 | $392K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 3,757 | 2,968 | $270K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.9% | 993 | 904 | $208K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 924 | 811 | $204K |
| 80053 | Comprehensive metabolic panel | 1.7% | 27,526 | 22,321 | $186K |
166 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 1,429 | $181K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 40,813 | $164K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 47,143 | $158K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 6,187 | $149K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 3,598 | $137K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 7,783 | $125K |
| 86738 | 1.1% | 10,960 | $119K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 700 | $113K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,848 | $98K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,137 | $94K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,081 | $83K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,282 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,243 | $70K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,396 | $63K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,009 | $61K |
| 72110 | <1% | 1,635 | $55K | |
| 87634 | <1% | 2,450 | $48K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,747 | $47K |
| 87040 | <1% | 5,398 | $40K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 4,080 | $39K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,233 | $38K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,052 | $37K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,761 | $37K |
| 84439 | <1% | 4,726 | $36K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 804 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,337 | $33K |
| 73564 | <1% | 1,410 | $33K | |
| 80061 | Lipid panel | <1% | 7,152 | $32K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,380 | $31K |
| 81001 | <1% | 15,828 | $31K | |
| 71250 | <1% | 1,036 | $30K | |
| 83880 | <1% | 2,679 | $30K | |
| 84484 | <1% | 10,863 | $30K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 371 | $30K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,939 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,461 | $25K |
| 83655 | <1% | 1,736 | $21K | |
| 86677 | <1% | 2,261 | $20K | |
| 80306 | <1% | 4,434 | $20K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,001 | $20K |
| 73030 | <1% | 1,010 | $20K | |
| 82542 | <1% | 8,224 | $20K | |
| 87088 | <1% | 5,574 | $19K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,372 | $19K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 79 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 169 | $15K |
| 82607 | <1% | 2,786 | $15K | |
| 85379 | <1% | 3,066 | $14K | |
| 85610 | <1% | 4,536 | $13K | |
| 73630 | <1% | 721 | $13K | |
| 73610 | <1% | 846 | $12K | |
| 82150 | <1% | 3,083 | $12K | |
| 76536 | <1% | 109 | $12K | |
| 83690 | <1% | 5,747 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,463 | $11K |
| 82550 | <1% | 7,693 | $11K | |
| 87070 | <1% | 1,156 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,637 | $11K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 73 | $10K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 47 | $10K |
| 83605 | <1% | 4,533 | $10K | |
| 85018 | <1% | 2,056 | $10K | |
| 72050 | <1% | 314 | $9K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 794 | $9K |
| 72131 | <1% | 107 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 537 | $8K |
| 81025 | <1% | 1,997 | $8K | |
| 83735 | <1% | 9,269 | $8K | |
| 73620 | <1% | 424 | $8K | |
| 87077 | <1% | 2,865 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,375 | $7K |
| 84703 | <1% | 2,744 | $7K | |
| 96376 | <1% | 2,451 | $7K | |
| 87186 | <1% | 2,756 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,987 | $6K |
| 87430 | <1% | 1,136 | $6K | |
| 83540 | <1% | 1,608 | $6K | |
| 85730 | <1% | 2,069 | $6K | |
| 82805 | <1% | 690 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,668 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,449 | $5K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 37 | $5K |
| 87428 | <1% | 575 | $5K | |
| 73130 | <1% | 267 | $4K | |
| 93017 | <1% | 91 | $4K | |
| 85651 | <1% | 2,255 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 23 | $4K |
| 72072 | <1% | 134 | $4K | |
| 97161 | <1% | 13 | $3K | |
| 74018 | <1% | 84 | $3K | |
| 86756 | <1% | 134 | $3K | |
| 82140 | <1% | 179 | $3K | |
| 82728 | <1% | 544 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 62 | $3K |
| 80074 | <1% | 516 | $3K | |
| 87400 | <1% | 482 | $3K | |
| 90715 | <1% | 219 | $3K | |
| 93971 | <1% | 32 | $3K | |
| 80076 | <1% | 846 | $2K | |
| 96367 | <1% | 56 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 13 | $2K |
| 73110 | <1% | 101 | $2K | |
| 70486 | <1% | 76 | $2K | |
| 87420 | <1% | 387 | $2K | |
| 73502 | <1% | 83 | $2K | |
| 83550 | <1% | 286 | $2K | |
| 82043 | <1% | 682 | $2K | |
| 82962 | <1% | 2,028 | $2K | |
| 86800 | <1% | 124 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,876 | $2K |
| 76775 | <1% | 12 | $1K | |
| 86376 | <1% | 149 | $1K | |
| 76642 | <1% | 14 | $1K | |
| 86703 | <1% | 158 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 357 | $1K |
| 99218 | <1% | 14 | $1K | |
| 86140 | <1% | 212 | $960.82 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,062 | $845.79 |
| 87522 | Neg quan hep c or qual rna | <1% | 37 | $830.39 |
| 94664 | <1% | 334 | $773.82 | |
| 85652 | <1% | 551 | $753.18 | |
| 99406 | <1% | 47 | $737.09 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,184 | $730.58 |
| 74022 | <1% | 28 | $725.16 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 75 | $629.76 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 300 | $572.71 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 149 | $571.59 |
| 86592 | <1% | 135 | $558.69 | |
| 86308 | <1% | 119 | $524.10 | |
| 93000 | <1% | 47 | $512.56 | |
| 82553 | <1% | 367 | $510.57 | |
| 73590 | <1% | 14 | $504.27 | |
| 73140 | <1% | 12 | $460.27 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 246 | $450.94 |
| 86038 | <1% | 60 | $369.44 | |
| 86431 | <1% | 71 | $349.79 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 18 | $337.48 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 209 | $269.95 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 201 | $240.81 |
| 73080 | <1% | 14 | $209.94 | |
| J3490 | Unclassified drugs | <1% | 330 | $200.92 |
| 51702 | <1% | 104 | $135.29 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 237 | $134.78 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 18 | $130.56 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 558 | $119.89 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 217 | $111.86 |
| 84550 | <1% | 40 | $85.13 | |
| 82565 | <1% | 25 | $70.14 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 75 | $66.84 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 140 | $62.90 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 303 | $55.69 |
| 36600 | <1% | 36 | $49.26 | |
| A9270 | Non-covered item or service | <1% | 2,095 | $46.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 41 | $45.31 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 298 | $41.23 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 163 | $28.04 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 131 | $15.07 |
| 87205 | <1% | 21 | $8.19 | |
| 87081 | <1% | 21 | $7.96 | |
| 84479 | <1% | 39 | $7.53 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 16 | $3.84 |
| 83615 | <1% | 22 | $2.50 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 98 | $1.66 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 20 | $1.10 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 17 | $0.00 |
| 84145 | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUCHTI, ROBERT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Buchanan General Hospital INC | Grundy, VA | $260K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.